{'fraction_non_alphanumeric': 0.02, 'fraction_numerical': 0.0, 'mean_word_length': 5.805825242718447, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interactions of the Anticancer Drugs Doxorubicin and Thaliblastine with Model Membranes and their Relation to Multidrug Resistance

ABSTRACT Interactions of the anticancer drugs doxorubicin (DOX) and thaliblastine (TBL) with model membranes composed of neutral and negatively charged membrane phospholipids were studied. Drug-phospholipid interactions were measured by differential scanning calorimetry and nuclear magnetic resonance. The membrane activities of DOX and TBL were compared to those of the multidrug resistance (MDR) modulators trans-flupentixol and verapamil. The results suggest that DOX and TBL are membrane active drugs. The impact of the drug-membrane activity on MDR is discussed.